Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01435525 |
Recruitment Status
:
Completed
First Posted
: September 16, 2011
Last Update Posted
: April 16, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Gastric Ulcer Duodenal Ulcer Gastric Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Idiopathic Thrombocytopenic Purpura Early Gastric Cancer |
Study Type : | Observational |
Actual Enrollment : | 369 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Nexium Capsules Specific Clinical Experience Investigation Concerning Helicobacter Pylori Eradication |
Study Start Date : | September 2011 |
Actual Primary Completion Date : | March 2014 |
Actual Study Completion Date : | March 2014 |

Group/Cohort |
---|
Nexium |
- Number of Adverse Drug Reactions [ Time Frame: Period from the start of triple therapy to assessment of eradication, an expected average of 3 months ]
- Rate of H.Pylori eradication [ Time Frame: Period from the start of triple therapy to assessment of eradication, an expected average of 3 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion criteria:
- Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric ulcer
- Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for duodenal ulcer
- Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric MALT lymphoma
- Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for idiopathic thrombocytopenic purpura
- Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for early gastric cancer
Exclusion Criteria:
- H.pylori negative at the time when the triple therapy is started

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01435525
Japan | |
Research Site | |
Aichi, Japan | |
Research Site | |
Akita, Japan | |
Research Site | |
Chiba, Japan | |
Research Site | |
Ehime, Japan | |
Research Site | |
Fukuoka, Japan | |
Research Site | |
Fukushima, Japan | |
Research Site | |
Gifu, Japan | |
Research Site | |
Gunma, Japan | |
Research Site | |
Hiroshima, Japan | |
Research Site | |
Hokkaido, Japan | |
Research Site | |
Hyogo, Japan | |
Research Site | |
Ibaraki, Japan | |
Research Site | |
Iwate, Japan | |
Research Site | |
Kagawa, Japan | |
Research Site | |
Kanagawa, Japan | |
Research Site | |
Kochi, Japan | |
Research Site | |
Kumamoto, Japan | |
Research Site | |
Kyoto, Japan | |
Research Site | |
Mie, Japan | |
Research Site | |
Miyagi, Japan | |
Research Site | |
Nagano, Japan | |
Research Site | |
Nagasaki, Japan | |
Research Site | |
Niigata, Japan | |
Research Site | |
Oita, Japan | |
Research Site | |
Okayama, Japan | |
Research Site | |
Okinawa, Japan | |
Research Site | |
Osaka, Japan | |
Research Site | |
Saitama, Japan | |
Research Site | |
Shiga, Japan | |
Research Site | |
Shimane, Japan | |
Research Site | |
Shizuoka, Japan | |
Research Site | |
Tokyo, Japan | |
Research Site | |
Toyama, Japan | |
Research Site | |
Wakayama, Japan | |
Research Site | |
Yamagata, Japan | |
Research Site | |
Yamanashi, Japan |
Study Director: | Shigeru Yoshida, MD | AstraZeneca K.K. |
Responsible Party: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT01435525 History of Changes |
Other Study ID Numbers: |
D961HC00011 |
First Posted: | September 16, 2011 Key Record Dates |
Last Update Posted: | April 16, 2014 |
Last Verified: | April 2014 |
Keywords provided by AstraZeneca:
triple therapy Helicobacter pylori eradication Nexium |
Additional relevant MeSH terms:
Ulcer Stomach Neoplasms Purpura Purpura, Thrombocytopenic Purpura, Thrombocytopenic, Idiopathic Stomach Ulcer Duodenal Ulcer Pathologic Processes Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Stomach Diseases |
Blood Coagulation Disorders Hematologic Diseases Hemorrhage Skin Manifestations Signs and Symptoms Thrombotic Microangiopathies Thrombocytopenia Blood Platelet Disorders Immune System Diseases Hemorrhagic Disorders Autoimmune Diseases Peptic Ulcer Duodenal Diseases Intestinal Diseases Esomeprazole |